Sunandana Chandra

机构：Northwestern University, Midwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University · ORCID：0000-0001-7936-5069

发表论文 194 篇 · 总被引 8760 次 · h-index 33

代表论文

• Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial (2025 · Nature Medicine · 被引 16)
• Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors (2025 · Journal for ImmunoTherapy of Cancer · 被引 13)
• HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors (2025 · Future Oncology · 被引 12)
• Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma (2024 · Clinical Cancer Research · 被引 8)
• Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient management (2025 · Journal of the American Academy of Dermatology · 被引 7)
• Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098. (2025 · Journal of Clinical Oncology · 被引 7)